Biogen marks a fresh 52-week high, shares extend NASDAQ biotech rally

Biogen touches a new 52-week high on NASDAQ as investors react to pipeline expansion, FDA Breakthrough Therapy status for salanersen and the RayThera deal, with Needham and Cantor Fitzgerald highlighting the stock’s prospects.

By Daniel Hoffmann, Chart & Technicals desk. Reviewed prior to publication on 2026-06-25, 18:20.

Biogen Inc. (US09062X1037) set a new 52-week high at 206.21 US dollars in recent NASDAQ trading, according to Investing.com data. The move comes as the biotech company’s shares benefit from a strengthened immunology pipeline and fresh regulatory momentum, while sector peers such as AbbVie and Amgen remain in focus for investors.

What the latest high shows

Investing.com reports that Biogen’s stock has climbed 61.26 percent over the past twelve months, underscoring a marked recovery phase for the large-cap biotech. The same report cites a current market capitalization of around 30.3 billion US dollars and a price-earnings ratio near 21.7, placing Biogen firmly in the S&P 500 healthcare cohort.

At the intraday peak of 206.21 US dollars, the shares reached their highest level in a year, pushing Biogen further up the NASDAQ biotechnology ranking. Third-party data provider InvestingPro continues to list the stock among its undervalued opportunities, pointing to a fair value estimate that still sits above the current quotation.

Analysts respond to pipeline moves

In parallel with the technical breakout, the stock benefits from a series of pipeline and M&A updates that have drawn analyst attention. Biogen recently agreed to acquire privately held RayThera Inc. for up to 1 billion US dollars, including an upfront payment and milestone-dependent tranches tied to future clinical and regulatory achievements. The deal adds several anti-inflammatory assets, with the lead program expected to enter Phase 1 studies in the early third quarter of 2026. Needham has responded by reiterating a Buy rating on Biogen and setting a price target of 255 US dollars, citing a positive outlook for the company’s commercial portfolio and forecasting a compound annual revenue growth rate of about 2 percent over the coming five years.

Beyond M&A, Biogen has secured Breakthrough Therapy Designation from the US Food and Drug Administration for salanersen, an investigational treatment for spinal muscular atrophy that is supported by Phase 1b data. The designation is designed to accelerate development and review processes for promising therapies, adding another regulatory catalyst to Biogen’s mid-term pipeline. Cantor Fitzgerald maintains an Overweight rating on the shares, focusing particularly on the BIIB080 program in Alzheimer’s disease and highlighting a mixed but increasingly constructive investment scenario around the stock. Additional market commentary compiled by StockTitan points to further recent news on CELIA Phase 2 data for diranersen (BIIB080) and updates on the priority review of LEQEMBI IQLIK subcutaneous injection, both of which broaden the overall neurology and neurodegeneration franchise.

The therapies behind the stock

Biogen generates most of its revenue from neurology and immunology, with flagship products such as LEQEMBI, developed jointly with Eisai, targeting early Alzheimer’s disease via anti-amyloid mechanisms. Alongside LEQEMBI, Biogen markets multiple sclerosis therapies and is building out a broader rare disease portfolio, including experimental assets like salanersen for spinal muscular atrophy and newer anti-inflammatory candidates sourced through transactions such as the RayThera acquisition.

Where the shares trade today

The Biogen shares (US09062X1037) trade on NASDAQ, with recent quotes around 205 US dollars and intraday highs at 206.21 US dollars as of June 25, 2026, 09:57 Eastern time. This places the stock close to its freshly established 52-week high and reflects the combination of pipeline newsflow and supportive analyst commentary seen over recent sessions.

Biogen at a glance

• Company: Biogen Inc.
• ISIN: US09062X1037
• WKN: 789617
• Ticker: BIIB
• Trading venue: NASDAQ
• Price (as of 2026-06-25, 09:57): 205.12 USD
• Market cap: 29.1 billion USD (as of 2026-06-25)
• Sector / industry: Biotechnology / Drug Manufacturers - General
• Index membership: S&P 500
• Next earnings date: not officially scheduled

This article provides factual information on Biogen’s shares and business without constituting investment advice or a recommendation to buy or sell securities.